Differences between antipsychotic drugs in persistence of brain levels and behavioral effects (Q48593246)

13 February 2018

http://europepmc.org/abstract/MED/1355924

title

Differences between antipsychotic drugs in persistence of brain levels and behavioral effects (English)

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

author name string

B M Cohen

1

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

T Tsuneizumi

2

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

R J Baldessarini

3

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

A Campbell

4

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

S M Babb

5

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

publication date

1 January 1992

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

published in

Psychopharmacology

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

volume

108

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

issue

3

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

page(s)

338-344

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

cites work

Pharmacokinetics of chlorpromazine after single and chronic dosage

1 reference

https://api.crossref.org/works/10.1007%2FBF02245121

Changes in Plasma Homovanillic Acid Concentrations in Schizophrenic Patients Following Neuroleptic Discontinuation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02245121

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02245121

Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF02245121

Simultaneous determination of haloperidol and its reduced metabolite in serum and plasma by isocratic liquid chromatography with electrochemical detection

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Behavioral effects of a single neuroleptic treatment grow with the passage of time

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Plasma HVA in psychiatric patients: longitudinal studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Prolonged pharmacologic activity of neuroleptic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Persistence of Haloperidol in the Brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Prolonged antidopaminergic actions of single doses of butyrophenones in the rat.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Bioavailability of psychotropic drugs: historical perspective and pharmacokinetic overview.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

DISSIPATION OF PHENOTHIAZINE EFFECT AND RECURRENCE OF SCHIZOPHRENIC PSYCHOSIS

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Absorption and excretion of tritiated haloperidol in man. (A preliminary report)

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Reduced haloperidol in the post-mortem brains of haloperidol-treated patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

PHENOTHIAZINE EXCRETION IN CHRONIC SCHIZOPHRENICS

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

In vivo effects of psychotropic agents on the physical properties of cell membranes in the rat brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Dopaminergic supersensitivity after neuroleptics: Time-course and specificity

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Anti-schizophrenic drugs—Membrane receptor sites of action

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Blood to brain distribution of neuroleptics

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Antipsychotic drugs, neurotransmitters, and schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Behavioral effects of (-)10,11-methylenedioxy-N-n-propylnoraporphine, an orally effective long-acting agent active at central dopamine receptors, and analogous aporphines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Malignant neuroleptic syndrome--its present status in Japan and clinical problems

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Variation in the single dose pharmacokinetics of fluphenazine in psychiatric patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Pharmacokinetics and effects of haloperidol in the isolated mouse

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

HPLC with electrochemical detection to measure chlorpromazine, thioridazine and metabolites in human brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Assay of plasma thioridazine and metabolites by high-performance liquid chromatography with amperometric detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Physiologic and clinical effects of chlorpromazine and their relationship to plasma level

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Decreasing sensitivity to neuroleptic agents in developing rats; evidence for a pharmacodynamic factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

FURTHER STUDIES OF CHLORPROMAZINE METABOLISM AND RELAPSE RATE.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Review of haloperidol blood level and clinical response: looking through the window

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Distribution and metabolism of neuroleptic drugs. I. Pharmacokinetics of haloperidol

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Chlorpromazine Metabolism in Chronic Schizophrenics

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study

1 reference

https://pubmed.ncbi.nlm.nih.gov/1355924

12 December 2020

Identifiers

DOI

10.1007/BF02245121

1 reference

13 February 2018

http://europepmc.org/abstract/MED/1355924

1 reference

13 February 2018